Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869319 · ClinicalTrials.gov registry record
Electronic Triggers: Messaging After A1C EHR Alert
A clinical trial of Hemoglobins and Diagnostic Tests, sponsored by NYU Langone Health.
- Completed
- Registry status
- 2,403
- Enrollment target
- 1
- Study location
NCT04869319 is a study of Hemoglobins and Diagnostic Tests that has completed, run by NYU Langone Health. The registered enrollment target is 2,403 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04869319, a study of Hemoglobins and Diagnostic Tests, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 2,403 participants
- Enrollment target
- 1
- Study location
Study Summary
Studying subjects with HbA1C tests \>10 and no follow-up test within 6 months and appointments scheduled in the next 60 days from data run date. Subjects who receive intervention message may be more likely to follow up with their provider to schedule a follow up HbA1C test.
Conditions Studied
Interventions
- BEHAVIORAL MyChart message
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,403 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2024-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04869319
The ClinicalTrials.gov registry entry for NCT04869319 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemoglobins appearing as the primary indexed condition, and to 1 intervention - of which MyChart message is the first listed.
NCT04869319 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04869319 about?
NCT04869319 is a clinical study titled "Electronic Triggers: Messaging After A1C EHR Alert". Studying subjects with HbA1C tests \>10 and no follow-up test within 6 months and appointments scheduled in the next 60 days from data run date. Subjects who receive intervention message may be more likely to follow up with their provider to schedule a follow up HbA1C test.
What is the current status of trial NCT04869319?
This trial is currently completed. The enrollment target is 2,403 participants. The study started on 2020-07-13. Estimated completion is 2024-03-28.
What conditions does trial NCT04869319 study?
This clinical trial studies the following conditions: Hemoglobins, Diagnostic Tests.
What interventions are being tested in trial NCT04869319?
The interventions under investigation include: MyChart message (BEHAVIORAL).
Who is sponsoring clinical trial NCT04869319?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04869319 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.